MAPK9 and non-small cell lung carcinoma: For instance, miRNAs regulated chemo-sensitivity in NSCLC treatment (Zhang Y. et al., 2014) and miR-146a promoted the chemosensitivity to cisplatin by targeting cyclin J (Shi et al., 2017) or JNK-2 (Pang et al., 2017) in NSCLC.